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local progression with rare hematogenous spread even
in the late stages of untreated disease.7 Even after
aggressive local control measures, locoregional recur-
rence is the fate of a majority of patients.8
Extended survival has been reported in patients
undergoing multimodality therapy of radical extrapleur-
al pneumonectomy followed by chemotherapy and radi-
ation.9-13 The difficulty in this management of the dis-
I t was estimated that 2200 to 3000 new cases of meso-thelioma would be diagnosed in the United States in
1998.1-3 The natural history of malignant pleural
mesothelioma includes a median survival of 4 to 12
months without intervention,4-6 and there is no accept-
ed standard therapy. The biologic behavior of malignant
pleural mesothelioma is unique among thoracic malig-
nant disease. It has shown a natural history of relentless
Objectives: Our aim was to identify prognostic variables for long-term
postoperative survival in trimodality management of malignant pleural
mesothelioma. Methods: From 1980 to 1997, 183 patients underwent
extrapleural pneumonectomy followed by adjuvant chemotherapy and
radiotherapy. Results: Forty-three women and 140 men (age range 31-76
years) had a median follow-up of 13 months. The perioperative mortal-
ity rate was 3.8% (7 deaths) and the morbidity, 50%. Survival in the 176
remaining patients was 38% at 2 years and 15% at 5 years (median 19
months). Univariate analysis identified 3 prognostic variables associated
with improved survival: epithelial cell type (52% 2-year survival, 21%
5-year survival, 26-month median survival; P = .0001), negative resec-
tion margins (44% at 2 years, 25% at 5 years, median 23 months; P =
.02), and extrapleural nodes without metastases (42% at 2 years, 17% at
5 years, median 21 months; P = .004). Using the Cox proportional haz-
ards, the relative risk of death was calculated for nonepithelial cell type
(OR 3.0, CI 2.0-4.5; P < .0001), positive resection margins (OR 1.7, CI
1.2-2.6; P = .0082), and metastatic extrapleural nodes (OR 2.0, CI 1.3-
3.2; P = .0026). Thirty-one patients with 3 positive variables had the best
survival (68% 2-year survival, 46% 5-year survival, median 51 months;
P = .013). A previously published staging system using these variables
stratified survival (P < .05). Conclusions: (1) Multimodality therapy
including extrapleural pneumonectomy is feasible in selected patients
with malignant pleural mesotheliomas, (2) pre-resectional evaluation of
extrapleural nodes may select patients for radical therapy, (3) micro-
scopic resection margins affect long-term survival, highlighting the need
for further investigation of locoregional control, and (4) patients with
epithelial, margin-negative, extrapleural node–negative resection had
extended survival. (J Thorac Cardiovasc Surg 1999;117:54-65)
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ease has been to differentiate patients most likely to
benefit from this aggressive approach from those
patients destined to die early of the disease. 
Since 1980, The Brigham and Women’s Hospital
applied extrapleural pneumonectomy for malignant
pleural mesothelioma in the context of trimodality ther-
apy. Two earlier reports of this series have reviewed the
results of 52 and 120 patients.13,14 We now review our
results with 183 consecutive patients and analyze prog-
nostic variables among the 176 long-term survivors.
These variables form the basis of a revision of our pub-
lished14 staging system. We also wish to assess the fea-
sibility of this approach in the light of this larger patient
cohort in preparation for future clinical trials and alter-
native treatment strategies. 
Patients and methods
We reviewed 183 consecutive patients with diffuse malig-
nant pleural mesothelioma treated with extrapleural pneu-
monectomy followed by adjuvant chemotherapy and radiother-
apy from 1980 to 1997 at The Brigham and Women’s Hospital,
the Dana-Farber Cancer Institute, and the Joint Center for
Radiation Therapy (Boston, Mass). Survival data were ob-
tained by reviewing hospital and office records and by contact-
ing patients or their primary care physicians. All surviving
patients were cross-sectionally contacted in September 1997.
All pathologic material establishing the diagnosis of malig-
nant pleural mesothelioma was reviewed by The Brigham and
Women’s Hospital Pathology Department for confirmation. If
a definitive diagnosis could not be made on tissue available,
a pleuroscopy and biopsy under direct vision was performed.
A multimodality team comprising a medical oncologist, a
surgeon, and a radiation oncologist evaluated all patients with
histologically proven malignant pleural mesothelioma. 
Patients were considered surgical candidates if they had a
Karnofsky performance status of greater than 70%, a creati-
nine level within normal limits, liver function test results
within the normal range, and tumor judged to be completely
resectable on the basis of computed tomographic scan, mag-
netic resonance imaging (MRI), and echocardiography.
Physiologic exclusion criteria included room air arterial PCO2
greater than 45 mm Hg, room air arterial PO2 less than 65 mm
Hg, echocardiography demonstrating an ejection fraction of
less than 45%, and a predicted postoperative forced expirato-
ry volume in 1 second (FEV1) of less than 1 L. Patients with
a preoperative FEV1 of less than 2 L underwent quantitative
radionuclide ventilation-perfusion scanning to predict post-
operative pulmonary function more accurately.
Trimodality treatment consisted of extrapleural pneu-
monectomy followed by postoperative intravenous chemo-
therapy and radiotherapy. Extrapleural pneumonectomy
entailed resection of the pleura, lung, diaphragm, and peri-
cardium en bloc.15 Separate resection of prior open biopsy
sites, thoracoscopy incisions, and chest tube tracks included a
1-cm margin of normal tissue.
A standardized pathologic analysis was routinely undertak-
en for each specimen. First, a gross examination of the spec-
imen was performed by the pathologist to determine any
obvious areas of tumor remaining at the resection margins.
Then, approximately 20 sections were taken through each
specimen to ascertain whether positive microscopic margins
remained along the chest wall. The bronchus, pericardium,
and diaphragm were carefully examined for microscopic
margins. A positive margin identified on the specimen was
then used to direct postoperative thoracic radiation treatment. 
Extrapleural pneumonectomy at our institution has always
included nodal sampling of hilar, paraesophageal, inferior
pulmonary ligament, peridiaphragmatic, and subcarinal nodal
stations. Additionally, right extrapleural pneumonectomies
had sampling of paratracheal nodes, and left extrapleural
pneumonectomies included sampling of aortopulmonary
window nodes. Involvement of these nodes has been deter-
mined in a standardized fashion by the same senior patholo-
gist (J. M. Corson) throughout this series of patients.
Extrapleural nodes are defined as mediastinal lymph nodes
and peridiaphragmatic lymph nodes not located within the
pleural reflection. Intrapleural nodes are defined as any
lymph node located within the pleural envelope. Each
patient’s status was staged by Butchart criteria,9 the new
international TNM mesothelioma staging system,16 and the
system previously published by this group.14
Chemotherapy was initiated 4 to 6 weeks after convales-
cence from extrapleural pneumonectomy. Nine patients treated
before 1985 received doxorubicin 50 to 60 mg/m2 and
cyclophosphamide 600 mg/m2 for 4 to 6 cycles. Eighty
patients treated from 1985 to 1994 also received cisplatin 70
mg/m2 added to the previous regimen (CAP). Ninety-four
patients undergoing treatment from 1995 to 1997 received
carboplatin (Paraplatin; Bristol Myers Squibb, Princeton, NJ)
and paclitaxel (Taxol; Bristol Myers Squibb) at dosages of an
area under the curve (AUC) of 6 and 200 mg/m2, respectively.
Although chemotherapy was started between 4 and 6 weeks
after extrapleural pneumonectomy, it was started up to 12
weeks after the operation if a patient had major postoperative
morbidity. Patients received 2 cycles of carboplatin/ paclitaxel
chemotherapy 3 weeks apart, followed by the prescribed
course of radiation therapy with concurrent weekly paclitaxel.
Beginning 3 to 4 weeks after completion of radiation therapy,
patients received 2 additional cycles of carboplatin and pacli-
taxel 3 weeks apart. 
External beam radiotherapy was delivered with the use of
linear accelerators ranging in energy from 4 to 15 MV. The
total radiation dose to the hemithorax was typically 30 Gy
delivered in 1.5-Gy fractions, and the mediastinum received 40
Gy. A boost dose was given to areas of gross residual disease,
localized positive resection margins, and/or localized lymph
nodes. The boost dose, if given, was typically 14 Gy in 2-Gy
fractions for a total cumulative dose to the boost region of 54 Gy. 
Because clinical symptoms and radiographic studies are not
sensitive enough to accurately diagnose early recurrence, the
disease-free interval is difficult to measure. Therefore survival
is the major end point of this study. The survival duration was
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measured from the date of extrapleural pneumonectomy until
the date of the patient’s last follow-up contact or death.
Perioperative mortality is defined as death occurring within 30
days of the operation. Morbidity is defined as an untoward
event directly resulting in prolonged hospitalization.
Statistical analysis of survival was undertaken by use of a
landmark of 30 days after surgical resection. Univariate
analysis was performed by means of the Kaplan-Meier life-
table method to determine the effects of demographic and
pathologic variables. The log rank test was used to determine
statistical significance of comparisons among survival
curves. Dichotomous variables included smoking history,
asbestos exposure, chest pain, dyspnea, cough, age greater or
less than 65 years, side of tumor, sex, cell type (epithelial ver-
sus mixed and sarcomatous), tumor at surgical margins, and
metastases to extrapleural nodes. Results with a P value of
less than .05 were considered significant and were included
in a multivariate proportional hazards regression model. This
generated an odds ratio of death for each variable associated
with shortened survival. 
Variables found to be significant on multivariate analysis
were used to modify our previously published surgical stag-
ing system. Log rank tests were used to determine the statis-
tical significance of survival comparisons between stage
groupings. 
Results
Demographics. The overall analysis included 183
patients who initiated therapy by undergoing extra-
pleural pneumonectomy at The Brigham and Women’s
Hospital from 1980 to 1997. The cohort included 43
women and 140 men with a mean age of 57 years
(range 31-76 years). Forty-nine (27%) patients were
aged 65 years or older. Median follow-up interval was
13 months (range 0.2-100 months) and follow-up is
complete through September 1997. Of the 183 patients,
117 (65%) reported a smoking history and 132 (75%)
had known asbestos exposure. One hundred two (56%)
reported a history of chest pain, 133 (73%) reported a
history of dyspnea, and 65 (36%) reported a history of
cough. Eighty-two patients (45%) had pleural mesothe-
lioma of the left side of the chest, and 101 had right-
sided tumors. 
Morbidity and mortality. Morbidity was divided
into major and minor subtypes. Major morbidity was
defined as an untoward event leading to longer hospital
stay and occurred in 45 of the 183 patients (24.5%).
Major cardiovascular morbidity occurred in 7 patients:
cardiac arrest (n = 5), right ventricular failure (n = 1),
and left ventricular failure (n = 1). Pulmonary morbid-
ity (n = 15) included patients with aspiration (n = 5),
pulmonary failure (n = 5), pulmonary embolus (n = 3),
and contralateral pneumothorax (n = 2). Infectious
morbidity (n = 9) causes included sepsis (n = 4), wound
infection (n = 3), empyema (n = 1), and bacteremia (n
= 1). Gastrointestinal morbidity (n = 7) included bleed-
ing in the upper gastrointestinal tract (n = 2), perforat-
ed duodenal ulcer (n = 2), colectomy for Clostridium
difficile colitis (n = 1), Ogilvie’s syndrome (n = 1), and
pancreatitis (n = 1). Technical morbidity (n = 12) in-
cluded patients who underwent re-exploration for
bleeding or suspected cardiac tamponade (n = 9),
diaphragmatic patch rupture (n = 2), and cardiac herni-
ation (n = 1). Other miscellaneous morbidity (n = 18)
included patients with vocal cord paralysis (n = 10),
deep venous thrombosis (n = 4), seizure (n = 2), and
acute renal failure (n = 2). 
Minor morbidity included atrial and ventricular
arrhythmias, which occurred in 75 patients (41%).
These arrhythmias were treated with cardioversion or
pharmacologic therapy without lengthening hospital
stay. Specifically, atrial fibrillation occurred in 68
patients (37%) and ventricular arrhythmias occurred in
7 patients (3.8%). Overall, some morbidity occurred in
92 patients (50%).
There were 7 perioperative (30-day) deaths (3.8%).
Three patients died of pulmonary embolus, 2 died of
myocardial infarction, 1 of cardiac herniation through a
pericardial defect, and 1 of respiratory failure. The
median postoperative length of stay was 9 days (range
5-101 days).
Long-term survival. The 30-day survival landmark
was reached by 176 patients. The median survival for
these patients was 19 months; 2- and 5-year survivals
were 38% and 15%, respectively (Fig 1). 
Demographic variables not significantly associated
with duration of survival within this group of 176 long-
term survivors included age greater than or equal to 65
years (P = .10 ), cigarette use (P = .33), asbestos expo-
sure (P = .38), chest pain (P = .15), dyspnea (P = .19),
cough (P = .92), and side of tumor (55% right; P = .70).
Female sex was associated with improved survival on
univariate analysis (P = .03) but was not significant in
the multivariate model (P = .16).
Epithelial cell type (Fig 2), negative resection mar-
gins (Fig 3), and lack of extrapleural lymph nodal
involvement (Fig 4) were significant prognostic factors
associated with prolonged survival in univariate analy-
sis. The 103 (59%) patients with epithelial cell type
tumors had 2- and 5-year survivals of 52% and 21%,
respectively (Fig 2). By contrast, the survival for the 73
patients with sarcomatous or mixed cell type was 16%
at 2 years, and no patient survived 5 years (P = .0001;
Fig 2). The 66 patients with negative resection margins
had a 2-year survival of 44% and a 5-year survival of
25% compared with the 110 patients with positive
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resection margins, who had a 2-year survival of 33%
and a 5-year survival of 9% (P = .02; Fig 3). The 136
patients with negative extrapleural nodal status had a 2-
year survival of 42% and a 5-year survival of 17%; the
40 patients with positive extrapleural nodal status had a
2-year survival of 23%, and none survived 5 years (P =
.004; Fig 4). Eleven patients had metastases to the
extrapleural peridiaphragmatic nodes but not to the
mediastinal nodes. We considered metastases to
extrapleural peridiaphragmatic nodes to act like metas-
tases to mediastinal nodes because they lay within the
same nodal drainage bed as the station 8 (peri-
esophageal) and station 9 (inferior pulmonary liga-
ment) nodes in the American Thoracic Society lymph
node map for lung cancer. 
The 4 significant variables identified by the log rank
test were entered in a Cox proportional hazards model.
Gender was no longer a significant predictor of long-
Fig 1. Kaplan-Meier survival curve for all patients surviving surgery (n = 176).
Fig 2. Kaplan-Meier survival curves for patients with epithelial versus sarcomatous and mixed disease (n = 176).
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term survival (P = .03). Odds ratios of death and confi-
dence intervals for the remaining 3 prognostic variables
are listed in Table I. 
Our previously published staging system14 was also
used to stage this cohort of patients. By this method,
survival was significantly stratified by stage (P = .048).
Median survival intervals for patients with stage I (n =
66), II (n = 41), and III (n = 69) disease were 25, 20,
and 16 months, respectively. The identification of these
predictive variables by the Cox proportional hazards
model led us to revise our previous staging system to
account for positive margins and extrapleural nodes
(Table II). When the criterion of extrapleural nodal
involvement was reassigned from stage II to stage III,
Fig 3. Kaplan-Meier survival curves of patients who had positive versus negative resection margins (n = 176). 
Fig 4. Kaplan-Meier survival curves for patients with positive extrapleural node involvement versus negative
extrapleural node involvement (n = 176).
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survival stratification was improved (Fig 5). This
revised staging system significantly stratified long-term
survival (P = .0011). This same cohort was not strati-
fied by the new international TNM system for mesothe-
lioma16 (P = .31) or by the Butchart staging system9 (P
= .09).
A subset of 31 patients with epithelial cell type, neg-
ative resection margins, and negative extrapleural nodal
status had a 51-month median survival with a 2-year
survival of 68% and a 5-year survival of 46% (Fig 6).
This most favorable group with stage I disease and
epithelial cell type had significantly better long-term
survival than did patients with stage II and stage III
epithelial disease (P = .0044). 
Discussion
This study suggests (1) multimodality therapy of
malignant pleural mesothelioma combining extrapleur-
al pneumonectomy with adjuvant chemoradiotherapy
is feasible with acceptable perioperative mortality
(3.8%); (2) a subgroup of patients with epithelial cell
type, negative extrapleural nodes, and complete resec-
tion margins have a long-term median survival
approaching 5 years; (3) research efforts should be
directed toward devising improved methods of obtain-
ing local control; (4) pre-resectional extrapleural node
Table I. Multivariate outcome of significant prognostic
variables (N = 183)
Variable N OR CI P value
Mixed or sarcomatous 73 3.0 2.0-4.5 <.0001
cell type
Positive resection margins 110 1.7 1.2-2.6 .0082
Metastatic extrapleural nodes 40 2.0 1.3-3.2 .0026
N, Number of patients; OR, odds ratio; CI, confidence interval.
Table II. The revised* staging system for malignant
pleural mesothelioma
Stage Description
I Disease completely resected within the capsule of the 
parietal pleura without adenopathy: ipsilateral pleura,
lung, pericardium, diaphragm, or chest wall disease 
limited to previous biopsy sites
II All of stage I with positive resection margins and/or 
intrapleural adenopathy
III Local extension of disease into the chest wall or 
mediastinum; heart, or through diaphragm, peritoneum; 
or with extrapleural lymph node involvement
IV Distant metastatic disease
Note: Patients with Butchart stage II and III9 disease are combined into stage
III. Stage I represents patients with resectable disease and negative nodes.
Stage II indicates resectable disease but positive nodes. 
*Revised from Sugarbaker DJ, Strauss GM, Lynch TJ, Richards W, Mentzer
SJ, Lee TH, et al. Node Status Has Prognostic Significance in the
Multimodality Therapy of Diffuse, Malignant Mesothelioma. J Clin Oncol
1993;11:1172-8; published with permission of WB Saunders Company).
Fig 5. Kaplan-Meier survival curves of all patients surviving surgery: stage I, n = 52; stage II, n = 84; and stage
III, n = 40. Revised staging system (n = 176; P = .0011).
60 Sugarbaker et al The Journal of Thoracic and
Cardiovascular Surgery
January 1999
staging may play an important role in deciding treat-
ment strategy; and (5) the staging system previously
published14 significantly stratified survival. Finally, we
propose a revision to our previously published staging
system. 
This study demonstrates in a large patient cohort that
extrapleural pneumonectomy is a safe means of cytore-
duction. In 1976, Butchart and associates9 reported
their experience with extrapleural pneumonectomy but
demonstrated a prohibitively high perioperative mortal-
ity rate of 31%. The advent of improved surgical tech-
niques, hemostasis, prosthetic reconstruction of the
diaphragm and pericardium, advances in intraoperative
and postoperative monitoring, and better critical care
support have since improved postoperative outcome to
our current rate of 7 deaths in 183 operations (3.8%
mortality). 
The major operative morbidity in this cohort was
24.5%, but many of the complications do not present
major setbacks when treated appropriately. Atrial fib-
rillation occurred in 37% but was well controlled with
calcium channel blockers, digoxin, procainamide, or a
combination of these agents. No patient had severe
consequences as a result of this complication. It is pos-
sible that rapid filling within the denuded hemithorax
results in respiratory distress because the dense fluid
shifts the mediastinum toward the remaining lung and
compresses it. Aspiration of the fluid-filled hemitho-
rax, as demonstrated in 6 of our patients, leads to repo-
sitioning of the mediastinum, decrease in intra-abdom-
inal pressure, and subsequent lung re-expansion
followed by resolution of hypoxia. The attendant mor-
bidity and potential mortality from extrapleural pneu-
monectomy stresses the importance of performing the
procedure at specialized institutions. 
The current regimen of combined carboplatin-pacli-
taxel adjuvant chemotherapy was designed in 1995.
Platinum-based chemotherapy yielded a response in 7
of 15 (47%) patients with peritoneal mesothelioma17
and in 18% with pleural mesothelioma.18 Paclitaxel as
a single agent in advanced pleural mesothelioma pro-
duced regression in 2 of 15 (13%) and stable disease in
5 of 15 (33%) patients treated by the Cancer and
Leukemia Group B (CALGB) in 1993.19 In 1995
Herscher and colleagues20 reported local control of
advanced pleural mesothelioma with single-agent
paclitaxel in 7 of 8 (88%) patients. Although there were
no combination data of carboplatin-paclitaxel in malig-
nant pleural mesothelioma, these 2 agents had recog-
nized single-agent activity against this chemotherapy-
resistant disease. Furthermore, there were published
data on the use of carboplatin-paclitaxel combinations
in the treatment of advanced breast, ovarian, and lung
cancers with high response rates: 78% to 94% in breast
Fig 6. Kaplan-Meier survival curves of patients with epithelial-type tumor: stage I, n = 31; stage II, n = 51; and
stage III, n = 21 (n = 103; P = .0044).
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cancer,21,22 57% to 81% in ovarian cancer,23,24 and 38%
to 86% in lung cancer.25-31 The rationale for this
approach has been steadily evolving in the literature.
Cisplatin and paclitaxel as single agents were each
effective against some in vivo mesothelioma cell lines
in athymic nude mice, but they were more effective in
all cell lines when given in combination.32
Carboplatin-paclitaxel was recognized as a better toler-
ated chemotherapy regimen than the CAP (cyclo-
phosphamide-doxorubicin-platinum) regimen it replaced.
Less toxicity for patients after pneumonectomy would
suggest more patients will receive adjuvant therapy. 
In other types of malignant disease, chemotherapy is
more effective in the setting of minimal residual tumor
burden,33 although this remains unproven in pleural
mesothelioma. 
Extrapleural pneumonectomy combined with adju-
vant chemoradiation therapy by this protocol offers
improved survival for certain subgroups of patients.
Specifically, patients with epithelial cell type, lack of
extrapleural nodal involvement, and negative surgical
margins have a median survival approaching 5 years.
The patients with non-epithelial cell type (sarcomatoid
and mixed cell type) have a significantly worse sur-
vival, with only 16% living for 2 years after the opera-
tion. This suggests that our current trimodality treat-
ment plan is having a small impact within this group
with unfavorable histologic features, and new strategies
for local control are needed. One possibility would be
to apply chemotherapy combinations currently admin-
istered in the treatment of sarcomas such as MAID
(methotrexate, Adriamycin [Pharmacia & Upjohn,
Kalamazoo, Mich], ifosfamide, and prednisone) in-
stead of carboplatin-paclitaxel combinations that have
demonstrated responses against epithelial tumors.
Mesothelioma, unlike lung cancer, tends to progress
locally rather than systemically. Of the 54% of patients
with recurrences reported by Baldini and colleagues,8
67% had recurrences within the ipsilateral hemithorax
and 50% had recurrences within abdominal regions; a
majority of these recurrences appeared to result from
direct extension from the ipsilateral hemithorax. Re-
currences are thought to result from trauma, spillage,
and residual tumor at the resection margins that subse-
quently are entrapped in fibrin deposits and become
exposed to postoperative growth factors.34 In this study,
patients with positive resection margins had a median
survival of 15 months (33% 2-year survival, 9% 5-year
survival) and patients with negative resection margins
had a median survival of 23 months (44% 2-year sur-
vival, 25% 5-year survival; P = .02). Our previous
report on the first 120 patients did not demonstrate this
finding,13 which we attribute to the larger number of
patients in the current study cohort. Taken together,
these observations suggest that future investigative
efforts should be directed toward more effective meth-
ods of locoregional control. 
Pass and colleagues35 have studied the role of intra-
operative photodynamic therapy as a method of local
control in the treatment of malignant pleural mesothe-
lioma. They have performed a phase I trial to determine
the maximally tolerated dose. However, they recently
published the results of a phase III trial indicating that
this treatment did not appear to prolong survival or
improve local control when performed after surgical
debulking.36
Rusch and colleagues37,38 have extensively studied
pleurectomy and postoperative intrapleural chemother-
apy. Their results have shown only marginal improve-
ment in outcome without significant toxicity. In
patients undergoing pleurectomy, gross residual tumor
frequently remains within the hemithorax. Given the
millimeter level of penetration of intracavitary chemo-
therapy, the amount of cytoreduction with pleurectomy
may be inadequate to allow the intracavitary chemo-
therapy to work optimally.39-42 In patients undergoing
extrapleural pneumonectomy, residual tumor within
the hemithorax is most often microscopic, presenting a
smaller tumor burden to be controlled with intracavi-
tary chemotherapy. Kodama and colleagues43 have used
hyperthermic intrathoracic chemotherapy in patients
undergoing resection for adenocarcinoma with evidence
of improved local control. No data exist in patients
with malignant pleural mesothelioma after surgical
resection.
The dismal survival of patients with extrapleural
nodal involvement suggests a role for pre-resectional
lymph node staging. Either mediastinoscopy or posi-
tron emission tomography (PET) scanning may play a
useful role in patient selection. Although paraesopha-
geal lymph nodes are inaccessible by mediastinoscopy,
a positive finding of a diseased mediastinal node is use-
ful nonetheless. Data on the detection of mediastinal
nodes via mediastinoscopy and PET scanning are
nonexistent in patients with mesothelioma. The pattern
of mesothelioma tumor spread does not appear to fol-
low an ordered lymphatic pattern like that seen in lung
cancer, and studies establishing the sensitivity and
specificity of mediastinoscopy in this particular disease
are needed. 
We recommend that patients with a histologic diag-
nosis of sarcomatoid or biphasic mesothelioma and
comorbid disease undergo mediastinoscopy because
the combination of both sarcomatoid or mixed cell
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types and positive extrapleural nodal status predicts a
survival that mimics the natural history without surgi-
cal intervention. If pre-resectional nodal testing proves
positive in high-risk patients with sarcomatoid or
mixed tumors, we would not recommend proceeding
with extended resection. 
The proposed International TNM Staging System16
and the Butchart staging system9 failed to stratify sur-
vival when applied to our cohort of 176 patients. The
TNM staging system placed 8% of our cohort into the
stage I category, 11% into stage II, 78% into stage III,
and 3% into stage IV. Since the majority of our cohort
of 176 patients were categorized as stage III by TNM,
it is difficult to separate patients with different tumor
characteristics that are necessary to stratify survival in
our patient cohort. In addition, the T descriptor alone
was not a statistically significant predictor of survival,
reflecting the inability of this system to describe the
biologic behavior of this particular tumor. 
The system proposed by Butchart similarly did not
significantly stratify survival. A small number of
patients were categorized as having stage III disease (n
= 5, 3%). The distinction between extent of primary
tumor involvement and intrathoracic nodal involve-
ment is not appropriately taken into account by this
staging system, as reflected by the majority of patients
being placed in the stage II category.
The staging system proposed previously by this
group14 continued to stratify survival successfully. This
is a surgical staging system based on the ability to com-
pletely remove all tumor within the pleural envelope
and involved regional nodes. Observer bias may exist
because this staging system originated at our institution
and was based on an earlier cohort. Validation by other
institutions will be required to judge the utility of this
clinical staging system. 
We considered peridiaphragmatic nodes to be
extrapleural nodes in this analysis. Metastasis to peridi-
aphragmatic nodes was associated with a similar medi-
an survival as metastasis to mediastinal nodes. How-
ever, if one considers only the 29 patients with
metastases to the mediastinal nodes that could be
reached by mediastinoscopy, there was a highly signif-
icant difference in long-term survival of these patients
compared with patients with uninvolved mediastinal
nodes (P = .0026).
Because of the negative effect of extrapleural nodal
disease on survival, we propose a revised staging sys-
tem to predict long-term survival (Table II). This stag-
ing system differs from our previous publication14 in
that the presence of extrapleural node involvement has
now been included in stage III. This represents a dis-
tinction as to the location and extent of nodal involve-
ment based on the poorer survival of patients in this
subgroup. 
A median survival of 51 months in the subgroup of
patients with negative extrapleural lymph nodes is a ray
of hope in the treatment of this dismal disease. We
believe it is no longer appropriate to offer only sup-
portive care to all patients with mesothelioma because
a subgroup of well-selected patients appears to benefit
from aggressive multimodality treatment (Fig 6). 
We thank John Orav, PhD, for his work on the statistics for
this paper and Mary Sullivan Visciano for editorial assistance.
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Discussion
Dr Larry R. Kaiser (Philadelphia, Pa). This series repre-
sents the largest series of extrapleural pneumonectomy to
date. We have seen data from some of these patients in earli-
er studies but now have the advantage of looking at the
mature data from 183 patients with a median follow-up inter-
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val of 13 months. Amazingly, the overall operative mortality
is a phenomenal 3.8%. This is truly impressive. 
The data further support the functional staging classification
originally proposed by Dr Sugarbaker and his colleagues and
now further revised and updated, which further adds to the
risk stratification and predictive value of this classification. 
I would like to expand on what Dr Sugarbaker has already
stated. Using his revised staging criteria, we can make better-
informed decisions regarding appropriate treatment for indi-
vidual patients. Not all patients with mesothelioma are in a
hopeless condition. A significant percentage of patients de-
serve an aggressive multimodality approach, as the Brigham
group has delineated. 
Dr Sugarbaker, to what do you attribute the absence of
adult respiratory distress syndrome (ARDS) in this large
group of patients undergoing extrapleural pneumonectomy?
Are you doing something we all should be doing? 
Obviously, patient selection is important. To what percent-
age of patients with malignant pleural mesothelioma do you
offer this multimodality approach? 
Do you have an arbitrary age cutoff, or is this individual-
ized? Are you performing mediastinoscopy routinely before
resection? 
This is an aggressive regimen. Do you have any quality-of-
life data from the first year of treatment? What percentage of
patients have grade IV toxicity during the postoperative
chemotherapy-radiotherapy regimen? 
Did you find MRI predictive of which patients should be
able to have at least a microscopically complete resection, if
not a complete resection? Can you base this on MRI criteria? 
Dr Sugarbaker. Thank you for your comments. I would
like to start by addressing the question of ARDS. We did have
some cases of ARDS, which contributed to the 25% morbid-
ity. ARDS is seen in the same percentage that one would
expect in patients undergoing pneumonectomy for non-small
cell lung cancer. 
However, we have selected these patients via MRI, looking
for resectable disease, and by echocardiogram, and we do
restrict intravenous fluids, probably not much different from
our standard pneumonectomy patients. Nevertheless, I won-
der what effect the screening for myocardial function would
have on patients undergoing pneumonectomy in general. It
may be helping, and it is an unseen benefit. 
We do not have an age cutoff, but most of the patients whom
we consider for this aggressive strategy are in their fifth or
sixth decade. Surprisingly, we are seeing an increasing num-
ber of patients in their 40s and 50s with the disease. That does
make one reconsider possible new causes, such as the simian
40 virus, but we do not have any specific age cutoff. 
We seriously consider using this therapy in about one third
of patients whom we see, so we see 3 or 4 for every single
patient whom we consider for extrapleural pneumonectomy
followed by trimodality therapy. 
In terms of mediastinoscopy, PET scanning, or laparoscopy
to get at retro-aortic or retro-paraesophageal nodes, these are
areas that need to be studied. Dr Rusch published a study on
the use of laparoscopy to detect transdiaphragmatic involve-
ment or intraperitoneal involvement, but I think we need to
move forward with an evaluation of the ability of medi-
astinoscopy to detect nodal disease in these patients. 
Notice that we very carefully suggested that these were
extrapleural nodes, and they are really a “grab bag” of medi-
astinal nodes, and that it is not clear how many of them would
be accessible via mediastinoscopy. Nevertheless, I believe that
PET will be an interesting tool for pre-resectional staging. 
Patients with sarcomatous disease who have positive medi-
astinal nodes on mediastinoscopy should not be considered
for aggressive therapy. Their survival is dismal despite an
aggressive approach and the resectability rate is low. 
We do not have data on the quality of life in these individ-
uals, but it is an important point and should be studied.
I do not have data on grade IV toxicity at hand. The reason
we switched from the CAP protocol (cytoxan, Adriamycin,
and then platinol), which was the most active combination
chemotherapy against mesothelioma, to carboplatin and
paclitaxel was precisely because of the incidence of grade IV
toxicity that prevented patients from completing the adjuvant
regimen. 
We consider MRI to be a better pre-resectional staging
modality than computed tomographic scanning, and we be-
lieve this has contributed significantly to the resectability rate
in our patients, which now approaches 80%. It is indeed supe-
rior for looking at mediastinal invasion or transdiaphragmat-
ic invasion.
Dr G. Alexander Patterson (St Louis, Mo). That was a
great paper, Dr Sugarbaker. However, I do not understand
why you are so light on the radiation. It seems to me that
when local control is the issue, you emphasize surgery over
radiation. I would have thought that 3000 rad was not quite
consistent with the magnitude of the local control you are try-
ing to achieve by that sort of an operation. How did you
decide on that particular radiation regimen?
Dr Sugarbaker. We arrived at that dose in a retrograde
fashion. We began with 5500 rad, the maximal cytologic dose,
to the ipsilateral hemithorax. When we combined that with
paclitaxel (Taxol) sensitization and the chemotherapy of car-
boplatin and paclitaxel, we found that a significant number of
patients were becoming neutropenic from the amount of mar-
row that was being radiated. The dose can go as high as 4000
rad, and it really depends on the patient’s blood count, but a
significant number of patients will become neutropenic from
the amount of rib marrow that is being radiated. 
Dr L. Penfield Faber (Chicago, Ill). Dr Sugarbaker, this is
an outstanding surgical series with a phenomenal mortality
rate of 3.8%. Surgeons who have done extrapleural pneu-
monectomy for mesothelioma fully realize what an achieve-
ment this is, as the earlier described mortality rates were
much higher. The current mortality rate in our series at the
Rush–Presbyterian–St Luke’s Medical Center is 7.5%.
Having done extrapleural pneumonectomies and removed
specimens that include the pleura, the pericardium, the lung,
and the diaphragm, I find it difficult to understand what con-
stitutes a negative microscopic margin. It can be technically
difficult to achieve a negative margin when removing the
The Journal of Thoracic and
Cardiovascular Surgery
Volume 117, Number 1
Sugarbaker et al   65
diaphragm from the inferior aspect of the posterior sulcus or
at the apex of the chest along the innominate vein and sub-
clavian vessels. You stated that this procedure is really a tech-
nique of cytoreduction, and it was implied that there may well
be residual microscopic disease. It is difficult for me to com-
prehend where the microscopic margins are negative and also
to understand how a surgical pathologist would evaluate and
dissect the specimen to identify negative microscopic mar-
gins. Please explain how negative microscopic margins are
achieved with this diffuse malignant tumor.
My second question refers to the possible toxic manifesta-
tions of paclitaxel coupled with radiation. We have recently
completed a pilot phase II study of neoadjuvant therapy for
clinically advanced lung cancer using paclitaxel in combina-
tion with radiation. We have observed significant complica-
tions after surgical resection when pretreating these patients
with paclitaxel and radiation. Because of these complications,
we no longer use paclitaxel in combination with radiation for
neoadjuvant therapy of lung cancer. I would appreciate hear-
ing any comments you might have on the toxic manifestations
of paclitaxel in your series.
Dr Sugarbaker. I appreciate your comments. The issue of
pathologic resection margins is an important one. The frus-
tration that you outlined—where would you take your sam-
ple, how would you approach a specimen—led Dr Joseph
Corson (professor of pathology at the Harvard Medical
School, and chief of surgical pathology until last year at The
Brigham and Women’s Hospital) to devise a systematic
method some 9 years ago for assessing these specimens; his
method involves systematically taking margins from 10 to 15
different points on the specimen, because trying to discern
where the specimen looked positive and where it looked neg-
ative led to a nonsystematic appraisal. 
Dr Corson or his fellow takes the specimen, inks it, and lets
us know exactly which of the sections is positive. I would
emphasize that in evaluating the survival curves we are look-
ing at a marker of cytoreduction. 
I am not suggesting that we are rendering patients disease-
free. However, if you think of 10 to 15 sections and you begin
to look at margins negative, margins positive, you are really
looking at a quantification of how well your local control pro-
cedure accomplished what it set out to do.
The most important lesson is that patients in whom we
have achieved near-complete cytoreduction appear to have a
survival advantage. This directs us toward local control
strategies, such as heated intrathoracic chemotherapy at the
time of resection, high-dose radiotherapy, photodynamic
therapy, and some of the other areas that would be used
against this particular tumor in its most vulnerable and most
lethal form, which is local recurrence. 
Last, I share your concern regarding paclitaxel radiotherapy.
We have found that it is unsuccessful as neoadjuvant therapy
in mesothelioma. We have performed extensive surgery after
induction therapy and have had a very high complication rate,
which led us to abandon that form of treatment. Sometimes
patients are referred who have already been treated. Those
patients do not do well. Paclitaxel radiotherapy is still an open
question. We have witnessed toxicity in conjunction with its
use. As Dr Patterson elucidated, we have had to reduce our
dose of radiotherapy to avoid toxicity in these patients.
